Plitidepsin for COVID-19: real-time analysis of 2 studies

Download Image

Post

c19early.org

Plitidepsin for COVID-19

2 studies with 163 patients

Serious outcome risk

Plitidepsin

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Plitidepsin studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (2)−16%

Mortality (2)−16%

RCTs (2)−16%

RCT mortality (2)−16%

Late (2)−16%

00.511.5+

← Plitidepsin
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


	Covid Analysis	Meta-analysis of plitidepsin studies
	Meta-analysis of plitidepsin studies
Dec 2 2024	PharmaMar, NCT05705167	A Multicentre, Open Label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin Versus Control in Immunocompromised Adult Patients With Symptomatic COVID-19 Requiring Hospital Care
	36% higher mortality (p=1). RCT 37 hospitalized immunocompromised patients, showing no significant benefit with plitidepsin treatment.
Aug 26 2024	Landete et al., Clinical Infectious Diseases, doi:10.1093/cid/ciae227	A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19
	1% lower mortality (p=1). RCT with 205 hospitalized moderate COVID-19 patients showing a trend towards faster time to sustained withdrawal of oxygen supplementation with plitidepsin treatment (1.5 mg/day or 2.5 mg/day for 3 days) compared to standard of care. The ..